comprehensive -WSS

comprehensive

author：knowledge 2025-09-27 22:48:33 - browse：366

WASHINGTON — Grail is aggressively lobbying to get Medicare to pay for its cancer-screening test Galleri — but experts tell STAT that the company has a far more complicated path to that end than the makers of most medicines or medical devices.

Grail’s controversial blood test Galleri screens for multiple cancers. The Food and Drug Administration has not yet approved it, so Medicare hasn’t had to make a decision on whether to cover it or not. Right now, most people pay for it out of pocket. It runs about $950.

In general, Medicare covers FDA-approved medicines and medical devices that help diagnose or treat disease or injury. But there’s a catch for Grail: Medicare doesn’t cover tests that simply screen healthy people, as Galleri does.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： FDA panel signals lack of confidence in Amgen cancer drug data

leisure time

WSS

Studies point to risks of excluding people with obesity from drug trials

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Senate committee scrutinizes Medicare Advantage brokers

Was Amgen transparent enough on FDA's concern on cancer drug?

Bill would stop addiction treatment from triggering child abuse inquiry

Bristol 'take

knowledge

comprehensive

Wikipedia

The high cost of giving birth even with insurance

First Opinion Podcast: Long Covid needs a new approach

The high cost of giving birth even with insurance

First Opinion Podcast: Long Covid needs a new approach

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Beam Therapeutics to lay off 20% of its staff, re

Bright Health sells Medicare Advantage business to Molina

VC firm General Catalyst wants to buy a health system

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Senate committee scrutinizes Medicare Advantage brokers

knowledge

CEOs share strategies for surviving biotech slump

STAT Summit: GSK CEO on pharma giant's new direction

Was Amgen transparent enough on FDA's concern on cancer drug?

Was Amgen transparent enough on FDA's concern on cancer drug?

Will Ozempic

STAT Summit: Michael J. Fox on progress in Parkinson's research

hotspot

leisure time

leisure time

focus